Peptilotbeta

Latest research

The peptide literature, summarized and graded.

Every paper distilled to a plain-language summary with an honest evidence grade — from strong human trials to animal-only signals. 1 papers indexed and counting.

Ask the literature →
Sourceallpaperstrialsyoutube
Evidenceallreviewinsufficientlimited humananimal onlymoderate humanin vitro onlystrong humanpreclinical mixed
CompoundGLP-1semaglutidetirzepatideretatrutidethymosin beta-4BPC-157TB-500cagrilintidesermorelinsurvodutideGHK-CumazdutidePT-141melanotan
Filtered by #TB-500 · clear
🧪 TrialInsufficient

TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD

Registered Phase 1/Phase 2 interventional trial (recruiting). This fictional study is an example of a ClinicalTrials.gov-style record. It describes a Phase 1/2 trial evaluating the safety and tolerability of TB-500 (a 17-23 fragment of thymosin beta 4) versus placebo in adults with stable atherosclerotic cardiovascular disease (ASCVD). Exploratory endpoints assess vascular function and inflammation biomarkers

#TB-500#thymosin beta-4
ClinicalTrials.gov · Mar 2026View trial ↗